Nur P. Damayanti
0000-0001-7166-1963
Publication & Citation Trends
Most Cited Works
Publications
266 total
Abstract 1727: Sequencing MEK inhibitor therapy after tovorafenib in BRAF fusion-driven cancers: Preclinical evidence of sustained tumor regression
Cited by 0
Semantic Scholar
EXTH-46. TESTING PRECISION GENOMICS-GUIDED THERAPY IN A MODEL OF ANAPLASTIC PLEOMORPHIC XANTHOASTROCYTOMA: DUAL INHIBITION OF CDK4/6 AND MEK
Cited by 0
Semantic Scholar
Establishment and characterization of patient-derived xenograft of a rare pediatric anaplastic pleomorphic xanthoastrocytoma (PXA) bearing a CDC42SE2-BRAF fusion OA
Cited by 0
Semantic Scholar
EXTH-43. TARGETING THE DNA DAMAGE RESPONSE THROUGH COMBINATION MDM2 AND AKT INHIBITOR THERAPY IMPROVES TEMOZOLOMIDE EFFECTIVENESS IN CHEMO-RESISTANT GLIOBLASTOMA OA
Cited by 0
Semantic Scholar
Abstract 5498: SHP2 inhibition enhances antitumor effect of mirdametinib in a pediatric brain tumor model bearing CDC42SE2BRAF fusion by rewiring the proteome and phosphoproteome landscape
Cited by 0
Semantic Scholar
GCN2 eIF2 kinase promotes prostate cancer by maintaining amino acid homeostasis PDF
Cited by 52
OpenAlex
Abstract 2017: Therapeutic induction of replication stress in the context of salvage therapy in osteosarcoma
Cited by 0
Semantic Scholar
Abstract 2011: Targeting CDK4/6 inhibitor resistance in relapsed RB-proficient osteosarcoma patient-derived xenografts via PI3 Kinase/mTOR inhibition
Cited by 0
Semantic Scholar
Research Topics
Renal and related cancers
(130)
Renal cell carcinoma treatment
(97)
Ferroptosis and cancer prognosis
(24)
Epigenetics and DNA Methylation
(20)
Cancer Genomics and Diagnostics
(20)
Frequent Co-Authors
Affiliations
Buffalo State University
Indiana University Health
University of Indianapolis
National Taiwan University of Science and Technology
Purdue University West Lafayette